Market access of biosimilars: not only a cost issue-Reference-Cited by-同舟云学术

Market access of biosimilars: not only a cost issue

Published:2011-05 Issue:5 Volume:13 Page:218-221
ISSN:1292-3818
Container-title:Oncologie
language:en
Short-container-title:Oncologie

Author:

Simoens S.,Verbeken G.,Huys I.

Publisher

Computers, Materials and Continua (Tech Science Press)

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10269-011-2018-8.pdf

Reference19 articles.

1. de Joncheere K, Rietveld A, Huttin C (2002) Experiences with generics. Int J Risk Safety Med 15: 101–109

2. Declerck PJ, Darendeliler F, Goth M, et al (2010) Biosimilars: controversies as illustrated by rhGH. Curr Med Res Opin 26: 1219–1229

3. European Generic Medicines Association (2010) EGA handbook on biosimilar medicines. European Generic Medicines Association, Brussels

4. European Medicines Agency (2006) Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing somatropin. European Medicines Agency, London

5. European Medicines Agency (2006) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. European Medicines Agency, London

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region;SpringerPlus;2016-12

2. Extending the Limits of Protection of Pharmaceutical Patents and Data Outside the EU – Is There a Need to Rebalance?;IIC - International Review of Intellectual Property and Competition Law;2014-03-25

3. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?;The European Journal of Health Economics;2013-11-23

4. BIOSIMILAR: AN OVERVIEW;International journal of pharmaceutical sciences and research;2013-06-01

5. Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act;Generics and Biosimilars Initiative Journal;2013-03-15